Yarlini Vipulanandan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yarlini Vipulanandan has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Claudette Poole
Department of Pediatrics University of Alabama at Birmingham Birmingham Alabama USA
1 shared publicationDavid W. Kimberlin
Department of Pediatrics University of Alabama at Birmingham Birmingham Alabama USA
1 shared publication
Latest Publications
- 15 August 2026
- Published by Wiley in Journal of Hospital Medicine
Clinical progress note: Hepatitis B
Hepatitis B virus is a well‐known infectious etiology of acute and chronic liver disease worldwide. Notably, 90% of children infected with hepatitis B in infancy develop chronic infection and subsequent progressive liver disease, including cirrhosis and hepatocellular carcinoma. Significant reduction in perinatal transmission in the United States (US) was seen after implementation of universal infant vaccination 30 years ago, as well as dramatic reductions in HBV incidence across Asia, coinciding with widespread hepatitis B vaccination. However, with ongoing changes to federal vaccine guidance and a steady rise in vaccine hesitancy, a comprehensive understanding of the epidemiology, transmission, screening, and prevention of hepatitis B remains important for pediatric health care providers.
- 15 August 2026
- Published by Wiley in Journal of Hospital Medicine
Clinical progress note: Hepatitis B
Hepatitis B virus is a well‐known infectious etiology of acute and chronic liver disease worldwide. Notably, 90% of children infected with hepatitis B in infancy develop chronic infection and subsequent progressive liver disease, including cirrhosis and hepatocellular carcinoma. Significant reduction in perinatal transmission in the United States (US) was seen after implementation of universal infant vaccination 30 years ago, as well as dramatic reductions in HBV incidence across Asia, coinciding with widespread hepatitis B vaccination. However, with ongoing changes to federal vaccine guidance and a steady rise in vaccine hesitancy, a comprehensive understanding of the epidemiology, transmission, screening, and prevention of hepatitis B remains important for pediatric health care providers.
- 28 December 2025
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (1) , e70093
Advancements and Uncertainties in the Treatment of Congenital CMV Disease
Congenital cytomegalovirus (CMV) is a large contributor to neurodevelopmental delay and non‐genetic related sensorineural hearing loss, which can often be delayed in onset. While a majority of CMV infections are asymptomatic in healthy children and adults, CMV infection of immunocompromised hosts and in utero infection in neonates can cause more clinically significant and potentially long‐term disease. Increased awareness of the significance of congenital CMV is reflected in the evolution of treatment recommendations over the past 20 years. Most therapeutic studies conducted thus far have focused on the treatment and outcomes of neonates with moderate to severe congenital CMV disease, while more recent studies have explored treatment for neonates and infants with CMV‐related isolated sensorineural hearing loss. This review focuses on the clinical significance and treatment of congenital CMV infection, as well as the potential role for universal newborn CMV screening.
- 28 December 2025
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (1) , e70093
Advancements and Uncertainties in the Treatment of Congenital CMV Disease
Congenital cytomegalovirus (CMV) is a large contributor to neurodevelopmental delay and non‐genetic related sensorineural hearing loss, which can often be delayed in onset. While a majority of CMV infections are asymptomatic in healthy children and adults, CMV infection of immunocompromised hosts and in utero infection in neonates can cause more clinically significant and potentially long‐term disease. Increased awareness of the significance of congenital CMV is reflected in the evolution of treatment recommendations over the past 20 years. Most therapeutic studies conducted thus far have focused on the treatment and outcomes of neonates with moderate to severe congenital CMV disease, while more recent studies have explored treatment for neonates and infants with CMV‐related isolated sensorineural hearing loss. This review focuses on the clinical significance and treatment of congenital CMV infection, as well as the potential role for universal newborn CMV screening.